Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetically proxied glucagon-like peptide-1 receptor perturbation and risk of mood disorders: a Mendelian randomization study.

BMC psychiatry - 6 Aug 2025

Jeon Yaejin, Kim Ju Han

Abstract excerpt

BACKGROUND: Glucagon-like peptide-1 receptor (GLP1R) agonists have gained attention for their role in diabetes treatment along with their diverse effects, such as appetite suppression, suggesting potential psychiatric benefits. This study aimed to assess the effect of GLP1R perturbation on mood disorders based on protein and biomarker levels using Mendelian randomization (MR) approach. METHODS: We conducted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Bipolar Disorder
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucagon-Like Peptide-1 Receptor

Share to Glycated Hemoglobin

Share to Major Depressive Disorder

Share to Mendelian Randomization Analysis

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 40770700
DOI: 10.1186/s12888-025-07152-0
PMCID: PMC12330103

Genes

GLP1R

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetically proxied glucagon-like peptide-1 receptor perturbation and risk of mood disorders: a Mendelian randomization study.PMID 40770700Read ↗

Glucagon-like peptide-1 receptor activation and mental health: a drug-target Mendelian randomization studySemantic proximity Read ↗

Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: evidence from a drug target Mendelian randomizationSemantic proximity Read ↗

Causal association between glucagon-like peptide-1 receptor agonists and mental disorders: insight from genetic and real-world evidence.Semantic proximity Read ↗

GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysisSemantic proximity Read ↗

Causes and consequences of major depressive disorder: An encompassing Mendelian randomization studySemantic proximity Read ↗

Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization studySemantic proximity Read ↗

Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization StudySemantic proximity Read ↗

Depression and type 2 diabetes risk: a Mendelian randomization study.Semantic proximity Read ↗

Depression and 24 Gastrointestinal Diseases: A Mendelian Randomization StudySemantic proximity Read ↗

Bi-directional Mendelian randomization and multi-phenotype GWAS show causality and shared pathophysiology between depression and type 2 diabetesSemantic proximity Read ↗

Depression and risk of gastrointestinal disorders: a comprehensive two-sample Mendelian randomization study of European ancestry.Semantic proximity Read ↗

Depression and 24 gastrointestinal diseases: a Mendelian randomization study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.